CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 1,467.7	$ 812.7
Marketable securities	1,342.2	596.8
Accounts receivable - trade, net	1,723.7	1,538.6
Accounts receivable from Sanofi	226.4	193.7
Accounts receivable from Bayer	293.1	242.0
Inventories	1,151.2	726.1
Prepaid expenses and other current assets	243.3	225.1
Total current assets	6,447.6	4,335.0
Marketable securities	1,755.0	1,486.5
Property, plant, and equipment, net	2,575.8	2,358.6
Deferred tax assets	828.7	506.3
Other noncurrent assets	127.4	77.9
Total assets	11,734.5	8,764.3
Current liabilities:
Accounts payable	218.2	178.2
Accrued expenses and other current liabilities	772.1	637.2
Deferred revenue, current	452.5	320.1
Total current liabilities	1,442.8	1,135.5
Capital and facility lease obligations	708.5	703.5
Deferred revenue, noncurrent	464.2	629.2
Other noncurrent liabilities	361.7	152.0
Total liabilities	2,977.2	2,620.2
Commitments and contingencies
Stockholders' equity:
Preferred Stock, $.01 par value; 30,0000,000 shares authorized; issued and outstanding - none	0.0	0.0
Additional paid-in capital	3,911.6	3,512.9
Retained earnings	5,254.3	2,946.7
Accumulated other comprehensive (loss) income	(12.3)	0.6
Treasury Stock, at cost; 3,990,021 shares in 2018 and 3,763,868 shares in 2017	(396.4)	(316.2)
Total stockholders' equity	8,757.3	6,144.1
Total liabilities and stockholders' equity	11,734.5	8,764.3
Class A Stock
Stockholders' equity:
Common stock	0.0	0.0
Total stockholders' equity	0.0	0.0
Common Stock
Stockholders' equity:
Common stock	0.1	0.1
Total stockholders' equity	0.1	0.1
Sanofi
Current liabilities:
Deferred revenue, current	246.7	177.7
Deferred revenue, noncurrent	279.3	379.9
Other
Current liabilities:
Deferred revenue, current	205.8	142.4
Deferred revenue, noncurrent	$ 184.9	$ 249.3